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Background

Poor neurodevelopmental outcomes and recurrences of cutaneous lesions remain unacceptably frequent among survivors of neonatal herpes simplex virus (HSV) disease.
Methods

We enrolled neonates with HSV disease in two parallel, identical, double-blind, placebo-controlled studies. Neonates with central nervous system (CNS) involvement were
enrolled in one study, and neonates with skin, eye, and mouth involvement only were
enrolled in the other. After completing a regimen of 14 to 21 days of parenteral acyclovir, the infants were randomly assigned to immediate acyclovir suppression (300 mg
per square meter of body-surface area per dose orally, three times daily for 6 months)
or placebo. Cutaneous recurrences were treated with open-label episodic therapy.
Results

A total of 74 neonates were enrolled — 45 with CNS involvement and 29 with skin,
eye, and mouth disease. The Mental Development Index of the Bayley Scales of Infant Development (in which scores range from 50 to 150, with a mean of 100 and
with higher scores indicating better neurodevelopmental outcomes) was assessed in
28 of the 45 infants with CNS involvement (62%) at 12 months of age. After adjustment for covariates, infants with CNS involvement who had been randomly assigned
to acyclovir suppression had significantly higher mean Bayley mental-development
scores at 12 months than did infants randomly assigned to placebo (88.24 vs. 68.12,
P = 0.046). Overall, there was a trend toward more neutropenia in the acyclovir
group than in the placebo group (P = 0.09).
Conclusions

Infants surviving neonatal HSV disease with CNS involvement had improved neurodevelopmental outcomes when they received suppressive therapy with oral acyclovir for 6 months. (Funded by the National Institute of Allergy and Infectious
Diseases; CASG 103 and CASG 104 ClinicalTrials.gov numbers, NCT00031460 and
NCT00031447, respectively.)
n engl j med 365;14
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T

he outcomes of neonatal herpes
simplex virus (HSV) disease are dependent
on the extent of the disease.1 Approximately
30% of babies with disseminated disease die, but
only 20% of survivors have neurologic sequelae.2
In contrast, only 6% of babies with central nervous
system (CNS) disease die, but approximately 70%
have permanent neurologic impairment.2 Skin, eye,
and mouth disease is not associated with death,
and neurologic impairment is rare with this manifestation of neonatal herpes.3
HSV establishes latency in sensory ganglia,
with periodic reactivation and recurrence of localized disease.4,5 Whether the virus subclinically reactivates in the brain after neonatal HSV disease
is not known. If reactivation in the brain does occur, it could contribute to the serious neurologic
sequelae associated with neonatal HSV disease
with CNS involvement, as has been suggested.6
Antiviral suppressive therapy prevents the recurrence of localized disease in persons with
genital7-10 or orolabial11,12 HSV infection. The National Institute of Allergy and Infectious Diseases
(NIAID) Collaborative Antiviral Study Group
(CASG) conducted parallel, identical, phase 3,
placebo-controlled studies of oral acyclovir suppressive therapy after neonatal HSV disease to
determine the efficacy and safety of long-term
antiviral administration during infancy.

Me thods
Study Design and Oversight

From August 1997 through April 2008, we enrolled infants with HSV disease in two trials: infants with CNS involvement (stratified according
to CNS disease alone or disseminated disease with
CNS involvement) were enrolled in the CASG 103
trial, and infants with skin, eye, and mouth disease only were enrolled in the CASG 104 trial. The
institutional review board at each participating institution approved the studies. The protocols, including the statistical analysis plans, are available
with the full text of this article at NEJM.org. All
authors vouch for the completeness and accuracy
of the data presented, as well as the fidelity of the
studies to the protocols. The NIAID convened a
data and safety monitoring board, which oversaw
the studies. Oral acyclovir and matching placebo
were supplied by GlaxoSmithKline, Alpharma
USPD, and Pharm Ops. None of these companies
had any role in the design or conduct of the trials,
the collection or analysis of the data, the prepan engl j med 365;14

ration of the manuscript, or the decision to submit
the manuscript for publication. Written informed
consent was obtained from a parent or guardian of
each study subject before study activities proceeded.
Study Population

Inclusion criteria for both studies were HSV infection, as confirmed by culture or, in the case of infants in the CASG 103 study who did not have skin
lesions, detection of HSV DNA in cerebrospinal
fluid by polymerase-chain-reaction (PCR) assay;
disease onset within the first 28 days of age; and
a body weight of at least 800 g at the time of enrollment. Infants in the CASG 103 study had to
have documentation of abnormal cerebrospinal
fluid indexes or abnormal findings on neuroimaging studies or electroencephalograms or had to
have cerebrospinal fluid that was positive for HSV
DNA, as detected by PCR assay, whereas subjects
in the CASG 104 study had normal results. In order for infants in the CASG 103 study to be eligible
to undergo randomization after the initial regimen
of parenteral acyclovir, they had to have cerebrospinal fluid that was negative for HSV DNA, as
detected by PCR assay, after completion of that
regimen.
The primary end point of both studies was
neurodevelopmental status at 12 months of age,
as assessed with the use of the Bayley Scales of
Infant Development, second edition. Secondary
end points were two or fewer recurrences of cutaneous lesions during the first 12 months of age
and detection by PCR assay of HSV DNA in the
cerebrospinal fluid during or after suppressive
therapy. The tertiary end point was toxic effects
of grade 2 or higher, as assessed with the use of
the World Health Organization (WHO) Toxicity
Grading Scale.13
All the infants completed a 14-day course (in
the case of the infants with skin, eye, and mouth
disease) or a 21-day course (in the case of infants
with CNS involvement) of parenteral acyclovir, as
is the standard of care.14 Infants in both studies
were then randomly assigned, in a 1:1 ratio, to oral
acyclovir or placebo, in a double-blind fashion. The
study drug was administered at a dose of 300 mg
per square meter of body-surface area, administered three times daily for 6 months.15 Per protocol, after an infant had a second cutaneous recurrence (i.e., exceeded the secondary end point), the
randomly assigned oral acyclovir or placebo was
discontinued, and open-label oral acyclovir suppression was allowed.
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Clinical and Safety Assessments

Assessments were performed at 2 weeks and
4 weeks after the first administration of the study
drug and then monthly throughout the 6-month
period during which the infants received suppressive treatment with the study drug or an openlabel drug. The infants were then seen at 1 year
of age for an assessment of end points. The neurodevelopmental pediatricians and psychologists
performing the Bayley Scales of Infant Development testing were not aware of the treatment assignments. Laboratory testing to assess safety was
performed at each visit during the period in which
the infants were receiving suppressive treatment.
Statistical Analysis

Demographic and baseline clinical characteristics
and results of the grading of laboratory-test abnormalities after intravenous acyclovir therapy
were compared with the use of the Kruskal–Wallis test for continuous variables and Fisher’s exact
test for categorical variables. For the primary efficacy analyses, a two-sample t-test was used to
determine whether assignment to suppressive therapy with oral acyclovir was associated with significantly improved neurodevelopmental outcomes at
12 months of age. An analysis-of-covariance model
was also used to adjust for baseline clinical factors that were unbalanced between the two treatment groups (P≤0.10). A Kaplan–Meier analysis
with a log-rank test was used to determine whether suppressive therapy with oral acyclovir reduced
the time to the second recurrence of skin lesions
and whether it prevented the appearance of HSV
DNA in the cerebrospinal fluid, as assessed by
PCR, during the 12-month period after completion of intravenous acyclovir therapy. Fisher’s exact test was used to compare toxic effects between
the two groups. A repeated-measures analysis was
used to compare the two groups with respect to
abnormalities in laboratory-test results during the
period from baseline to month 6.

R e sult s
Demographic and Baseline Characteristics
of the Subjects

A total of 45 infants underwent randomization at
19 institutions as part of the CASG 103 study —
37 with CNS disease and 8 with disseminated disease and CNS involvement; 29 infants with skin,
eye, and mouth disease underwent randomization
at 12 institutions as part of the CASG 104 study.
1286
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As shown in Table 1, the two groups in each study
were balanced with respect to the extent of neurologic involvement, viral type, and gestational age.
Infants with CNS disease who were randomly
assigned to acyclovir, as compared with those
assigned to placebo, had a lower median birth
weight (P = 0.01), median weight at study enrollment (P = 0.01), and median head circumference
at birth (P = 0.03). Infants with skin, eye, and mouth
disease who were randomly assigned to acyclovir,
as compared with those assigned to placebo,
had lower median weight at enrollment (P = 0.03)
(Table 1 in the Supplementary Appendix, available
at NEJM.org).
Of the 45 infants in the CASG 103 (CNS) study,
39 (87%) either completed 6 months of therapy
(23 subjects) or had two recurrences of cutaneous
lesions (16); the other 6 infants did not complete
the full 6 months of therapy for the following reasons: loss to follow-up (1 infant), nonadherence to
the protocol (2), withdrawn consent (2), and death
(1 in the placebo group) (Fig. 1A). The baseline
characteristics of the 6 infants who did not complete 6 months of treatment did not differ significantly from those of the infants who did.
Of the 29 infants in the CASG 104 (skin, eye,
and mouth disease) study, 26 (90%) either completed 6 months of therapy (12) or reached the
study end point after two cutaneous recurrences
(14); the other 3 infants did not complete the full
6 months of therapy because of loss to follow-up
(1) and nonadherence to the protocol (2) (Fig. 1B).
The baseline characteristics of the 3 infants who
did not complete 6 months of treatment did not
differ significantly from those of the infants
who did.
Cutaneous Recurrences

The likelihood of skin recurrences after neonatal
HSV disease is not affected by disease classification.3 In an analysis that included data from the
74 infants in the two studies combined and that
evaluated the time to discontinuation of the study
medication because the infant had two cutaneous
recurrences, the median time the infants received
the study drug was 2.5 months longer among infants assigned to acyclovir than among those assigned to placebo (P = 0.009) (Fig. 2C). In the CASG
103 (CNS) study, the median time the infants received the study drug was 4.1 months longer
among infants assigned to acyclovir than to those
assigned to placebo (P = 0.04) (Fig. 2A). In the CASG
104 (skin, eye, and mouth disease) study, the me-
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Table 1. Baseline Demographic and Clinical Characteristics, According to Study-Drug Assignment.*
Characteristic

CASG 103
CNS Disease

CASG 104

Disseminated Disease
with CNS Involvement

Skin, Eye, and Mouth Disease

acyclovir
(N = 21)

placebo
(N = 16)

acyclovir
(N = 3)

placebo
(N = 5)

acyclovir
(N = 15)

placebo
(N = 14)

Median

37

38

40

39

38

39

Range

25–41

35–40

40–41

38–40

27–40

27–41

Gestational age — wk

HSV type — no./total no. (%)†
I

2/14 (14)

3/11 (27)

1/2 (50)

1/3 (33)

5/12 (42)

5/11 (45)

II

12/14 (86)

8/11 (73)

1/2 (50)

2/3 (67)

7/12 (58)

6/11 (55)

Median

91.5

109.0

3.0

2.0

4.0

6.0

Range

10–1216

5–58,080

1–18

0–13

0–20

0–33

Positive

17/21 (81)

12/16 (75)

2/3 (67)

3/5 (60)

Negative

4/21 (19)

4/16 (25)

1/3 (33)

2/5 (40)

White-cell count in cerebrospinal fluid at presentation
— cells/mm3

HSV DNA in cerebrospinal fluid at presentation —
no./total no. (%)‡

Evidence of HSV disease on MRI — no./total no. (%)
Abnormal EEG — no./total no. (%)

0
14/14 (100)

0
13/13 (100)

10/16 (62)

9/14 (64)

1/3 (33)

0

0

0

9/13 (69)

10/14 (71)

1/1 (100)

0

NA

NA

* None of the characteristics differed significantly between the groups (P>0.05 for all comparisons). EEG denotes electroencephalogram, HSV
herpes simplex virus, MRI magnetic resonance imaging, and NA not applicable.
† The viral type was unknown in the case of some infants.
‡ HSV DNA in cerebrospinal fluid was detected with the use of a polymerase-chain-reaction assay.

dian time the infants received the study drug was
1.7 months longer among infants assigned to acyclovir than to those assigned to placebo (P = 0.24)
(Fig. 2B). In a regression analysis of the two thirds
of infants for whom the viral type was known
(Table 1), the likelihood of cutaneous recurrences was not affected by viral type.
Recurrences of CNS Disease

Three infants in the CASG 103 study had a recurrence of CNS disease during the 12 months after
enrollment in the study. Two had been assigned
to placebo (both term babies), and one had been
assigned to acyclovir (a 28-week premature infant)
(P = 0.59). All three had cerebrospinal fluid that
was positive for HSV DNA, as detected by PCR
assay, at the time of the recurrence of CNS disease and had an adequate therapeutic and virologic response to another course of parenteral acyclovir, suggesting that acyclovir resistance was
unlikely. During the same period, no infant in the
CASG 104 study had a recognized occurrence of
CNS disease.
n engl j med 365;14

Neurodevelopmental Outcomes

A total of 28 of the 45 infants (62%) enrolled in
the CASG 103 (CNS) study had a Bayley Scales of
Infant Development assessment at 12 months (Fig.
1A). Baseline demographic and clinical characteristics, including assessments of the extent of
neurologic involvement, were similar between the
28 subjects who had a Bayley Scales of Infant Development assessment at 12 months of age and
the 17 who did not (Table 2, and Table 2 in the
Supplementary Appendix). For subjects with CNS
disease, an analysis-of-covariance model was used
to adjust for the covariates at baseline that were
unbalanced between the groups. The covariates
that were examined included age at enrollment,
birth weight, weight at enrollment, head circumference at birth, head circumference at enrollment,
Apgar scores at 1 and 5 minutes, gestational age,
the presence of cutaneous lesions during the initial illness, and viral type (HSV-1 or HSV-2). After
adjustment for covariates that had P values of
0.10 or less (head circumference at birth, birth
weight, and enrollment weight), infants assigned
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10 Underwent
Bayley Scales
of Infant
Development
assessment
at 12 mo

15 Completed
6 mo of
randomly
assigned
oral acyclovir

n engl j med 365;14

nejm.org

5 Underwent
Bayley Scales
of Infant
Development
assessment
at 12 mo

1 Underwent
Bayley Scales
of Infant
Development
assessment
at 12 mo

7 Received
2 Did not
open-label
receive openacyclovir sup- label acyclovir
pression after suppression
two cutaneous
after two
recurrences
cutaneous
recurrences

9 Did not
complete
6 mo of
randomly
assigned
oral acyclovir

24 Were assigned
to receive acyclovir

6 Underwent
Bayley Scales
of Infant
Development
assessment
at 12 mo

5 Underwent
Bayley Scales
of Infant
Development
assessment
at 12 mo

1 Underwent
Bayley Scales
of Infant
Development
assessment
at 12 mo

9 Received
4 Did not
open-label
receive openacyclovir sup- label acyclovir
pression after suppression
two cutaneous
after two
recurrences
cutaneous
recurrences

13 Did not
complete
6 mo of
randomly
assigned
placebo

21 Were assigned
to receive placebo

8 Completed
6 mo of
randomly
assigned
placebo

45 Infants were included
in CASG 103 (CNS) study

B

6 Underwent
Bayley Scales
of Infant
Development
assessment
at 12 mo

8 Completed
6 mo of
randomly
assigned
oral acyclovir

2 Underwent
Bayley Scales
of Infant
Development
assessment
at 12 mo

0 Underwent
Bayley Scales
of Infant
Development
assessment
at 12 mo

5 Received
2 Did not
open-label
receive openacyclovir sup- label acyclovir
pression after suppression
two cutaneous
after two
recurrences
cutaneous
recurrences

7 Did not
complete
6 mo of
randomly
assigned
oral acyclovir

15 Were assigned
to receive acyclovir

2 Underwent
Bayley Scales
of Infant
Development
assessment
at 12 mo

4 Completed
6 mo of
randomly
assigned
placebo

5 Underwent
Bayley Scales
of Infant
Development
assessment
at 12 mo

0 Underwent
Bayley Scales
of Infant
Development
assessment
at 12 mo

9 Received
1 Did not
open-label
receive openacyclovir sup- label acyclovir
pression after suppression
two cutaneous
after two
recurrences
cutaneous
recurrences

10 Did not
complete
6 mo of
randomly
assigned
placebo

14 Were assigned
to receive placebo

29 Infants were included in CASG 104
(Skin, Eye, and Mouth) study
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Figure 1. Enrollment, Randomization, and Follow-up in the Two Parallel Studies.
The CASG 103 study (Panel A) included neonates who had HSV disease with central nervous system (CNS) involvement. The yellow boxes represent the 15 infants with a Bayley
Scales of Infant Development mental-development assessment at 12 months who received active suppression for 6 months, either with the randomly assigned oral acyclovir for
the entire 6-month period (10 infants) or with the randomly assigned oral acyclovir for part of the time and open-label oral acyclovir for part of the time (5 infants); the blue boxes
represent the 6 infants with a mental-development assessment at 12 months who received acyclovir suppression for only part of the 6-month treatment period; and the pink boxes
represent the 7 infants with a mental-development assessment at 12 months who received no acyclovir suppression at any time during the study. The CASG 104 study (Panel B)
included neonates who had HSV disease with skin, eye, and mouth involvement.
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Figure 2. Time to Discontinuation of Study Drug.
Per protocol, the study drug was discontinued if an
infant had two cutaneous recurrences. The time to
discontinuation of the study drug is shown among
subjects in the CASG 103 study (Panel A), which included neonates with HSV disease with central nervous system (CNS) involvement, among subjects in
the CASG 104 study (Panel B), which included neonates with HSV disease with skin, eye, and mouth
involvement only, and among the subjects in the two
groups combined (Panel C).

A Infants with CNS Involvement

0.6

Acyclovir

0.4
Placebo
0.2
P=0.04 by log-rank test
0

2

4

6

8

Months Receiving Study Drug
No. at Risk
Acyclovir
Placebo

24
21

24
14

19
12

8
4

1
0

B Infants with Skin, Eye, and Mouth Involvement
Probability of Event-free Survival

1.0
0.8
0.6
0.4

Acyclovir

Placebo
0.2
P=0.24 by log-rank test
0.0

0

2

4

6

8

Months Receiving Study Drug
No. at Risk
Acyclovir
Placebo

15
14

14
11

11
9

6
3

0
0

C Total Cohort
1.0
0.8
Acyclovir

0.6
0.4

Placebo
0.2
P=0.009 by log-rank test
0.0

0

2

4

6

8

Months Receiving Study Drug
No. at Risk
Acyclovir
Placebo

Safety Assessments

0.8

0.0

Probability of Event-free Survival

to receive acyclovir had significantly higher mean
Bayley mental-development scores at 1 year (88.24
vs. 68.12, P = 0.046). Among subjects in the CASG
103 (CNS) study assigned to suppressive therapy
with oral acyclovir, 69% had normal neurologic
outcomes, 6% had mild impairment, 6% had moderate impairment, and 19% had severe impairment;
the corresponding proportions among subjects
assigned to placebo were 33%, 8%, 25%, and 33%.
Among subjects in the CASG 104 (skin, eye, and
mouth) study, no significant differences in Bayley
mental-development scores were noted. In a regression analysis of data from the two thirds of subjects
for whom the viral type was known (Table 1),
neurodevelopmental outcomes did not differ significantly according to viral type in either study.
A total of 15 infants in the CASG 103 (CNS)
study received suppressive therapy with oral acyclovir for the entire 6-month study-drug period
(Fig. 1A, yellow boxes), whereas 6 infants received
acyclovir suppression for part of the 6-month treatment period (Fig. 1A, light blue boxes) and 7 subjects received no active suppression throughout
the study (Fig. 1A, pink boxes). The 12-month Bayley mental-development scores were incrementally higher as infants were receiving acyclovir
suppression for longer periods of time: among infants receiving suppressive therapy for 6 months,
the mean (±SE) scores were 85±5 (median, 91);
among infants receiving suppressive therapy for
less than 6 months, the mean scores were 80±8
(median, 70); and among infants receiving no
suppressive therapy, the mean scores were 73±10
(median, 58). Bayley motor-development scores did
not differ significantly between the groups in either study.

Probability of Event-free Survival

1.0

39
35

38
25

30
21

14
7

1
0

There was no significant difference in absolute
neutrophil counts between the infants receiving lute neutrophil count of 500 cells per cubic miloral acyclovir and those receiving placebo in ei- limeter or less in the combined studies did not
ther study (Table 3). The time to the first abso- differ significantly between the infants assigned
n engl j med 365;14
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Table 2. Demographic and Clinical Characteristics of Infants with and without 12-Month Bayley Scales of Infant Development
Assessments.*
Characteristic

CASG 103 (CNS) Study
Bayley
Assessment
(N = 28)

No Bayley
Assessment
(N = 17)

Median

39.5

Range

28–41

Bayley
Assessment
(N = 15)

No Bayley
Assessment
(N = 14)

38

38

39

25–40

27–41

27–40

2/13 (15)

8/10 (80)

11/13 (85)

2/10 (20)

P Value

Gestational age — wk

0.17

HSV type — no./total no. (%)†
7/19 (37)

II

12/19 (63)

0/11
11/11 (100)

White-cell count in cerebrospinal fluid at
presentation — cells/mm3
65

71

Range

1–58,080

0–1216

HSV DNA in cerebrospinal fluid at presentation — no./total no. (%)‡

0.48
6

5

0–20

2–33

0.16
19/28 (68)

Negative

0.003

0.98

Median

15/17 (88)

P Value
0.69

0.03

I

Positive

CASG 104 (Skin, Eye, and Mouth) Study

0.22
0/15
15/15 (100)

0/12

9/28 (32)

2/17 (12)

Evidence of HSV disease on MRI — no./
total no. (%)

13/23 (57)

7/13 (54)

1.00

0

12/12 (100)
0

Abnormal EEG — no./total no. (%)

14/19 (74)

6/12 (50)

0.26

NA

NA

—

* EEG denotes electroencephalogram, HSV herpes simplex virus, MRI magnetic resonance imaging, and NA not applicable.
† The viral type was unknown in the case of some infants.
‡ HSV DNA in cerebrospinal fluid was detected with the use of a polymerase-chain-reaction assay.

to acyclovir and those assigned to placebo, although a trend for neutropenia was noted among
those who received acyclovir (P = 0.09). In total,
an absolute neutrophil count of 500 cells per cubic millimeter or less developed in 25% of the
subjects in the CASG 103 (CNS) study and in 20%
of those in the CASG 104 (skin, eye, and mouth)
study who were assigned to acyclovir, as compared
with 5% and 7%, respectively, of those who were
assigned to placebo. Neutropenia resolved in all
the affected infants, in some cases with and in
other cases without cessation of suppressive therapy, and none had associated complications.
No significant differences between the groups
were seen with respect to other hematologic or
chemical laboratory tests or with respect to adverse events or serious adverse events (Table 3 in
the Supplementary Appendix). There were no adverse events that led to discontinuation of the
study drug.
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Discussion
Therapeutic studies of rare diseases such as neonatal herpes present unique challenges. Each of
the previous major investigations of the management of neonatal HSV conducted by the CASG has
spanned the course of a decade.2,3,16,17 The current studies were no exception, requiring 11 years
to enroll 74 infants. Many clinicians assumed that
oral acyclovir would be efficacious, on the basis
of the results of small, uncontrolled studies,18,19
further challenging the conduct of these randomized, controlled trials. The long-term follow-up
required to assess neurodevelopmental outcomes
also affected the ability to follow all the enrolled
infants for the primary protocol end point, with
only 43 of the 74 infants (58%) having a Bayley
Scales of Infant Development assessment at 12
months (Fig. 1A and 1B).
Interpretation of the results of the neurode-
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Table 3. Maximum Change in Absolute Neutrophil Count during Receipt of Antiviral Suppressive Therapy.*
Change

CASG 103 (CNS) Study
Acyclovir
(N = 24)

Placebo
(N = 21)

CASG 104 (Skin, Eye, and Mouth) Study
Acyclovir
(N = 15)

Placebo
(N = 14)

no. of infants/total no. (%)
Worsening by ≥2 grades

5/22 (23)

3/18 (17)

2/13 (15)

0/13

Worsening by 1 grade

3/22 (14)

2/18 (11)

2/13 (15)

5/13 (38)

13/22 (59)

13/18 (72)

4/13 (31)

6/13 (46)

5/13 (38)

2/13 (15)

No change
Improvement by ≥1 grade

1/22 (5)

0/18

* Grading was performed with the use of the World Health Organization Toxicity Grading Scale.13 The absolute neutrophil count was not measured in some of the infants. P=0.94 and P=0.24 for the comparison of acyclovir with placebo in
the CASG 103 study and the CASG 104 study, respectively.

velopmental assessment should be tempered by
the fact that Bayley Scales of Infant Development
assessments were not performed in 38% of subjects in the CASG 103 (CNS) study. This substantial attrition renders the primary protocol end
point less interpretable. For the 62% of infants in
the CASG 103 study with a neurologic evaluation
at 12 months, our finding of improved neurodevelopmental outcomes among subjects who started oral acyclovir suppression at the end of the
21-day course of intravenous therapy provides the
first controlled data that suggest that ongoing
neurologic injury occurs in infants who survive
neonatal HSV disease and that it can be decreased
by longer-term antiviral suppression. This finding
had previously been implied in small, uncontrolled
case series.6,19
The distribution of neurologic outcomes among
infants in the CASG 103 (CNS) study who were
randomly assigned to placebo (normal, 33%; mild
impairment, 8%; moderate impairment, 25%; severe impairment, 33%) was similar to that among
infants in an earlier trial (in whom the neurologic
outcomes were measured by a different tool) who
received high-dose parenteral acyclovir for the
treatment of acute disease but no subsequent suppression (normal, 31%; mild impairment, 15%;
moderate impairment, 15%; severe impairment,
39%).2 Similarly, the distribution of outcomes
among infants in the CASG 103 (CNS) study who
were randomly assigned to oral acyclovir was virtually identical to that from a small, uncontrolled
case series (involving 16 infants) of oral acyclovir
suppression after neonatal HSV CNS disease (69%
with normal outcomes in both studies).19 The

n engl j med 365;14

finding of incrementally higher neurodevelopmental scores among infants treated with oral antiviral suppressive therapy for the full 6 months as
compared with those treated for only part of the
6 months and as compared with those who received no antiviral suppression (median 12-month
Bayley mental-development score of 91 vs. 70 and
58, respectively) also supports the conclusion that
oral acyclovir suppressive therapy after treatment
of acute neonatal HSV disease confers a benefit.
If the infants who were randomly assigned to
placebo had not been allowed to switch to active
suppression after two cutaneous recurrences, it is
possible that the difference between the acyclovir
and placebo groups would have been more pronounced. In addition, the subjects with CNS disease who were randomly assigned to acyclovir were
smaller in size than were those assigned to placebo, as reflected in the lower birth weights and
smaller head circumferences. However, any bias
introduced by this difference should be in favor
of the null hypothesis, since prematurity or smallfor-gestational-age status would be more likely to
be associated with worse developmental outcomes.
Not surprisingly,7-12 these studies provided evidence that suppressive therapy with oral acyclovir decreases the number of recurrences of cutaneous lesions after neonatal HSV disease, as has
been suggested previously.15 Since skin lesions
occur in approximately 70% of all babies with
neonatal HSV,1 the positive socioeconomic effect
of decreased recurrences should not be underestimated. For example, prevention of skin recurrences can translate to the need for fewer medical
evaluations and to more days of child care atten-
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dance, which in turn results in fewer days of work
missed by the parent.
Previous uncontrolled studies have suggested
that acyclovir therapy may be associated with neutropenia.2,15,20-24 In the current placebo-controlled
studies, neutropenia was not more likely to develop
in infants receiving acyclovir than in infants receiving placebo, although the P values approached
significance. It is possible that there is indeed an
association that our studies were underpowered to
detect; thus, we believe that neutropenia should
continue to be considered as a possible toxic effect of longer-term oral acyclovir therapy.15
These data support the use of suppressive
therapy with 300 mg of oral acyclovir per square
meter per dose administered three times daily for
6 months after initial treatment of neonatal HSV
disease. Babies with skin, eye, and mouth disease
can benefit because this therapy helps to prevent

skin recurrences, whereas babies with CNS disease may have additional benefit with respect to
neurodevelopmental outcomes. There are no controlled data that suggest that suppressive therapy
administered longer than 6 months or with the
use of higher doses of oral acyclovir is beneficial.
An extemporaneously compounded oral solution
of valacyclovir has not been sufficiently studied in
neonates and young infants to warrant its use instead of oral acyclovir for antiviral suppression.25
Presented in part at the 48th Annual Meeting of the Infectious Diseases Society of America, Vancouver, BC, Canada, October 22, 2010; abstract 2977.
Supported by contracts (N01-AI-30025, N01-AI-65306, N01AI-15113, and N01-AI-62554) with the Division of Microbiology
and Infectious Diseases of the National Institute of Allergy and
Infectious Diseases (NIAID). Oral acyclovir and matching placebo were supplied by GlaxoSmithKline, Alpharma USPD, and
Pharm Ops.
Disclosure forms provided by the authors are available with
the full text of this article at NEJM.org.
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